The Experts below are selected from a list of 6 Experts worldwide ranked by ideXlab platform
Masayuki Shimizu - One of the best experts on this subject based on the ideXlab platform.
-
topical Tocoretinate improved hypertrophic scar skin sclerosis in systemic sclerosis and morphea
Journal of Dermatology, 1999Co-Authors: Hitoshi Mizutani, Toshimichi Yoshida, Nobuhiro Nouchi, Hiroko Hamanaka, Masayuki ShimizuAbstract:Four patients with systemic scleroderma (SSc), 4 patients with morphea, and 4 patients with hypertrophic scar were treated with topical Tocoretinate for 6 months to 3 years and studied clinically and histopathologically. Clinically, all of the lesions responded to this therapy. The stiffness of the skin lesions, glossy appearance of the lesions, and telangiectasia improved. Histopathologically, the proliferated collagen fibers decreased in thickness, and the inter-fiber spaces increased. Immunoreactive tenascin-C expressed in the proliferated deep dermal fibers of the SSc and hypertrophic scar lesions was markedly decreased compared with the level before the topical Tocoretinate therapy. Topical Tocoretinate has been used for the treatment of ulcers; it is also a potent treatment for sclerotic skin diseases.
Hitoshi Mizutani - One of the best experts on this subject based on the ideXlab platform.
-
topical Tocoretinate improved hypertrophic scar skin sclerosis in systemic sclerosis and morphea
Journal of Dermatology, 1999Co-Authors: Hitoshi Mizutani, Toshimichi Yoshida, Nobuhiro Nouchi, Hiroko Hamanaka, Masayuki ShimizuAbstract:Four patients with systemic scleroderma (SSc), 4 patients with morphea, and 4 patients with hypertrophic scar were treated with topical Tocoretinate for 6 months to 3 years and studied clinically and histopathologically. Clinically, all of the lesions responded to this therapy. The stiffness of the skin lesions, glossy appearance of the lesions, and telangiectasia improved. Histopathologically, the proliferated collagen fibers decreased in thickness, and the inter-fiber spaces increased. Immunoreactive tenascin-C expressed in the proliferated deep dermal fibers of the SSc and hypertrophic scar lesions was markedly decreased compared with the level before the topical Tocoretinate therapy. Topical Tocoretinate has been used for the treatment of ulcers; it is also a potent treatment for sclerotic skin diseases.
Toshimichi Yoshida - One of the best experts on this subject based on the ideXlab platform.
-
topical Tocoretinate improved hypertrophic scar skin sclerosis in systemic sclerosis and morphea
Journal of Dermatology, 1999Co-Authors: Hitoshi Mizutani, Toshimichi Yoshida, Nobuhiro Nouchi, Hiroko Hamanaka, Masayuki ShimizuAbstract:Four patients with systemic scleroderma (SSc), 4 patients with morphea, and 4 patients with hypertrophic scar were treated with topical Tocoretinate for 6 months to 3 years and studied clinically and histopathologically. Clinically, all of the lesions responded to this therapy. The stiffness of the skin lesions, glossy appearance of the lesions, and telangiectasia improved. Histopathologically, the proliferated collagen fibers decreased in thickness, and the inter-fiber spaces increased. Immunoreactive tenascin-C expressed in the proliferated deep dermal fibers of the SSc and hypertrophic scar lesions was markedly decreased compared with the level before the topical Tocoretinate therapy. Topical Tocoretinate has been used for the treatment of ulcers; it is also a potent treatment for sclerotic skin diseases.
Nobuhiro Nouchi - One of the best experts on this subject based on the ideXlab platform.
-
topical Tocoretinate improved hypertrophic scar skin sclerosis in systemic sclerosis and morphea
Journal of Dermatology, 1999Co-Authors: Hitoshi Mizutani, Toshimichi Yoshida, Nobuhiro Nouchi, Hiroko Hamanaka, Masayuki ShimizuAbstract:Four patients with systemic scleroderma (SSc), 4 patients with morphea, and 4 patients with hypertrophic scar were treated with topical Tocoretinate for 6 months to 3 years and studied clinically and histopathologically. Clinically, all of the lesions responded to this therapy. The stiffness of the skin lesions, glossy appearance of the lesions, and telangiectasia improved. Histopathologically, the proliferated collagen fibers decreased in thickness, and the inter-fiber spaces increased. Immunoreactive tenascin-C expressed in the proliferated deep dermal fibers of the SSc and hypertrophic scar lesions was markedly decreased compared with the level before the topical Tocoretinate therapy. Topical Tocoretinate has been used for the treatment of ulcers; it is also a potent treatment for sclerotic skin diseases.
Hiroko Hamanaka - One of the best experts on this subject based on the ideXlab platform.
-
topical Tocoretinate improved hypertrophic scar skin sclerosis in systemic sclerosis and morphea
Journal of Dermatology, 1999Co-Authors: Hitoshi Mizutani, Toshimichi Yoshida, Nobuhiro Nouchi, Hiroko Hamanaka, Masayuki ShimizuAbstract:Four patients with systemic scleroderma (SSc), 4 patients with morphea, and 4 patients with hypertrophic scar were treated with topical Tocoretinate for 6 months to 3 years and studied clinically and histopathologically. Clinically, all of the lesions responded to this therapy. The stiffness of the skin lesions, glossy appearance of the lesions, and telangiectasia improved. Histopathologically, the proliferated collagen fibers decreased in thickness, and the inter-fiber spaces increased. Immunoreactive tenascin-C expressed in the proliferated deep dermal fibers of the SSc and hypertrophic scar lesions was markedly decreased compared with the level before the topical Tocoretinate therapy. Topical Tocoretinate has been used for the treatment of ulcers; it is also a potent treatment for sclerotic skin diseases.